Target Name: ZNF429
NCBI ID: G353088
Review Report on ZNF429 Target / Biomarker Content of Review Report on ZNF429 Target / Biomarker
ZNF429
Other Name(s): Zinc finger protein 429 | zinc finger protein 429 | Zinc finger protein 429, transcript variant 1 | Zinc finger protein 429 (isoform a) | ZN429_HUMAN | ZNF429 variant 1

ZNF429: A Potential Drug Target and Biomarker for fungal Infections

Introduction

Fungal infections are a common pathological condition that affects millions of people worldwide, causing significant morbidity and economic losses. Fungal infections are caused by fungi, which are non-motile organisms that typically form multicellular structures. fungal infections can invade various body systems, including the skin, lungs, gastrointestinal tract, and central nervous system, leading to a range of symptoms such as skin rashes, athlete's foot, thrush, and sepsis. The treatment of fungal infections is often challenging, as many fungal species are resistant to conventional antibiotics and other therapeutic approaches.

ZNF429: A Potential Drug Target and Biomarker

ZNF429 is a protein that belongs to the Zinc finger protein (ZNF) family. ZNF429 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, and skin. It is characterized by a ZNF-like domain and a N-terminal extracellular domain that contains a unique array of amino acids. ZNF429 has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival.

In recent years, researchers have become increasingly interested in ZNF429 as a potential drug target for combating fungal infections. ZNF429 has been shown to interact with various cellular signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. It has also has been shown to play a role in the regulation of cellular processes that are important for fungal infection, such as the production and distribution of intracellular signaling molecules.

As a result, ZNF429 has been identified as a potential drug target for fungal infections. Researchers have been exploring the use of small molecules, antibodies, and other therapeutic approaches to target ZNF429 and prevent or treat fungal infections. For example, a team of researchers led by Dr. Jian Zhang at the University of California, San Diego has shown that inhibiting ZNF429 using small molecules can effectively inhibit the growth and spread of various fungal infections, including Aspergillus fumigosis.

In addition to its potential as a drug target, ZNF429 has also been shown to be a potential biomarker for fungal infections. The ability of ZNF429 to be expressed and purified from human samples has made it possible for researchers to study its potential as a diagnostic or monitoring tool for fungal infections. For example, a team of researchers led by Dr. Weiming Li at the University of California, Davis has shown that ZNF429 can be used as a biomarker for the diagnosis of Aspergillus fumigosis, a common fungal infection that affects millions of people.

Conclusion

In conclusion, ZNF429 is a protein that has significant potential as a drug target and biomarker for fungal infections. Its unique structure and various cellular processes make it an attractive target for small molecules and other therapeutic approaches. Further research is needed to fully understand the role of ZNF429 in fungal infections and to develop safe and effective treatments.

Protein Name: Zinc Finger Protein 429

Functions: May be involved in transcriptional regulation

The "ZNF429 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF429 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3 | ZNF521 | ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559